Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - CHINOOK THERAPEUTICS, INC. | adro-ex311_7.htm |
| EX-32.1 - EX-32.1 - CHINOOK THERAPEUTICS, INC. | adro-ex321_8.htm |
| EX-31.2 - EX-31.2 - CHINOOK THERAPEUTICS, INC. | adro-ex312_11.htm |
| EX-10.46 - EX-10.46 - CHINOOK THERAPEUTICS, INC. | adro-ex1046_1070.htm |
| EX-10.45 - EX-10.45 - CHINOOK THERAPEUTICS, INC. | adro-ex1045_1071.htm |
| EX-10.44 - EX-10.44 - CHINOOK THERAPEUTICS, INC. | adro-ex1044_1240.htm |
| 10-K - 10-K - CHINOOK THERAPEUTICS, INC. | adro-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-203508 and 333-210016 on Form S-8, and Registration Statement No. 333-211063 on Form S-3 of our report dated March 1, 2017, relating to the consolidated financial statements of Aduro Biotech, Inc. and subsidiaries (the “Company”) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2016.
/s/ DELOITTE & TOUCHE LLP
San Francisco, California
March 1, 2017